Home-based Intervention With Semaglutide Treatment Of Neuroleptica-Related Prediabetes

Korábbi kezelés

• Previous treatment with study drug or use of other weight reducing drugs within the last 6 month
• Participation in other drug trials
• Treatment with drugs approved for overt diabetes type 2. (Metformin not included)

Más betegség

• Active malignant disease within the last 5 years

Laborértékek

• Diagnosis of diabetes (T1D or T2D) or a HbA1c >47 mmol/mol
• Significant somatic disease: 1) end-stage renal failure (eGFR <15 ml/min); 2) elevated liver function tests (liver transaminases >2 times upper normal limit); 3) history of acute or chronic pancreatitis; 4) heart failure (NYHA class IV) or unstable angina pectoris or myocardial infarction with the last 6 months; 5) uncontrolled hypertension (systolic blood pressure >180 mm Hg, diastolic blood pressure >100 mm Hg)

Egyéb

• Pregnancy or breast feeding
• Exceeding high risk consumption limit (>21 / 14 units of alcohol for men / women, respectively) or severe substance abuse
• Unwillingness to allow home visits by a study nurse
• Circumstances that the investigator believes will interfere with the trial

• Diagnosed with schizophrenia spectrum disorder (ICD10 codes DF20, DF21 or DF25)
• Age between 18 and 60 years (both included)
• Approved contraception for female participants
• Treated by one of the OPUS clinics and or community psychiatry centers teams and community psychiatry in the Region of Southern Denmark or Zealand
• Antipsychotic SGA treatment for at least 6 months
• Stable co-medication for at least 1 month
• HbA1c between 39-47 mmol/mol (both included). Two measurements with ≥3 month interval are required to confirm prediabetes. The first measurement is identified and obtained from patient journals, the second prior to enrolment
• BMI ≥27 kg/m2. Two weights with ≥3 month interval are required to confirm obesity
• Capable of providing informed oral and written consent